Neratinib联合卡培他滨对比拉帕替尼联合卡培他滨治疗经≥2线抗HER2治疗的HER2阳性转移性乳腺癌:III期NALA试验
NALA是一项随机、活性对照、III期试验,比较不可逆泛HER酪氨酸激酶抑制剂(TKI)Neratinib联合卡培他滨(N+C)与可逆双重TKI拉帕替尼联合卡培他滨(L+C)在中心确认的HER2阳性转移性乳腺癌(MBC)且既往接受≥2线抗HER2治疗的患者中的疗效。共入组621例患者,N+C组307例,L+C组314例。主要终点为盲态独立中心评估的无进展生存期(PFS)和总生存期(OS)。结论认为N+C显著改善PFS和至CNS疾病干预时间,安全性可控。
核心结论
- 在既往接受≥2线抗HER2治疗的HER2阳性转移性乳腺癌患者中,N+C较L+C显著改善PFS和至CNS疾病干预时间,OS无显著差异。
研究设计与样本
- 随机、活性对照、III期试验(NALA,NCT01808573),入组621例中心确认HER2阳性转移性乳腺癌患者,按1:1随机分配至N+C组(307例)或L+C组(314例)。
- 患者既往接受≥2线抗HER2转移性治疗方案,包括稳定无症状CNS疾病患者。
- N+C方案:Neratinib 240 mg每日一次+卡培他滨750 mg/m2每日两次(第1-14天,每21天),联合洛哌丁胺预防腹泻。
- L+C方案:拉帕替尼1250 mg每日一次+卡培他滨1000 mg/m2每日两次(第1-14天,每21天)。
- 共同主要终点为盲态独立中心评估的PFS和OS,α分割;若任一主要终点达到即认为试验阳性。
关键数值与推荐
- N+C组最常见全等级不良事件为腹泻(83% vs 66%)和恶心(53% vs 42%)。
- 两组停药率和健康相关生活质量(HRQoL)相似。
- 未观察到N+C新的安全性信号。
临床怎么用
- 对于既往接受≥2线抗HER2治疗的HER2阳性转移性乳腺癌患者,N+C可作为有效治疗选择,显著改善PFS。
- N+C可能降低CNS疾病干预需求,对存在稳定无症状CNS疾病患者可考虑使用。
- 使用N+C时需进行洛哌丁胺预防以管理腹泻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: NALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, a reversible dual TKI, plus capecitabine (L+C) in patients with centrally confirmed HER2-positive, metastatic breast cancer (MBC) with ≥ 2 previous HER2-directed MBC regimens. METHODS: Patients, including those with stable, asymptomatic CNS disease, were randomly assigned 1:1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m2 twice a day 14 d/21 d) with loperamide prophylaxis, or to lapatinib (1,250 mg once every day) plus capecitabine (1,000 mg/m2 twice a day 14 d/21 d). Coprimary end points were centrally confirmed progression-free survival (PFS) and overall survival (OS). NALA was considered positive if either primary end point was met (α split between end points). Secondary end points were time to CNS disease intervention, investigator-assessed PFS, objective response rate (ORR), duration of response (DoR), clinical benefit rate, safety, and health-related quality of life (HRQoL). RESULTS: A total of 621 patients from 28 countries were randomly assigned (N+C, n = 307; L+C, n = 314). Centrally reviewed PFS was improved with N+C (hazard ratio [HR], 0.76; 95% CI, 0.63 to 0.93; stratified log-rank P = .0059). The OS HR was 0.88 (95% CI, 0.72 to 1.07; P = .2098). Fewer interventions for CNS disease occurred with N+C versus L+C (cumulative incidence, 22.8% v 29.2%; P = .043). ORRs were N+C 32.8% (95% CI, 27.1 to 38.9) and L+C 26.7% (95% CI, 21.5 to 32.4; P = .1201); median DoR was 8.5 versus 5.6 months, respectively (HR, 0.50; 95% CI, 0.33 to 0.74; P = .0004). The most common all-grade adverse events were diarrhea (N+C 83% v L+C 66%) and nausea (53% v 42%). Discontinuation rates and HRQoL were similar between groups. CONCLUSION: N+C significantly improved PFS and time to intervention for CNS disease versus L+C. No new N+C safety signals were observed.
引用
- Saura C, Oliveira M, Feng YH, et al. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol. 2020. PMID: 32678716. doi:10.1200/JCO.20.00147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。